---
id: 140
title: Hepatitis C Virus (HCV) Treatment with Direct-Acting Antivirals
category: organisms
subcategory: viruses
tags: [HCV, hepatitis-C, DAAs, sofosbuvir, glecaprevir-pibrentasvir, SVR]
difficulty: medium
---

## Question

How is HCV treated? Use the **"Treat All HCV RNA+ with Pangenotypic DAAs × 8-12 Weeks, Cure >95%"** framework.

## Answer

### **Hepatitis C Treatment Principles:**

**Universal Treatment:**
- **Treat ALL HCV RNA-positive patients** (regardless of fibrosis stage)
- **Goal:** Sustained virologic response (SVR) = cure
- **SVR = HCV RNA undetectable 12 weeks after treatment completion**

### **Preferred Pangenotypic Regimens (2024):**

**First-Line (No Cirrhosis or Compensated Cirrhosis):**

| Regimen | Duration | Genotype Coverage | Notes |
|---------|----------|-------------------|-------|
| **Sofosbuvir/velpatasvir (Epclusa)** | **12 weeks** | **All genotypes (1-6)** | **Most common first-line**, well-tolerated |
| **Glecaprevir/pibrentasvir (Mavyret)** | **8 weeks** (treatment-naive, no cirrhosis) **12 weeks** (compensated cirrhosis) | **All genotypes (1-6)** | **Shortest duration**, contraindicated if decompensated cirrhosis (Child-Pugh B/C) |
| **Sofosbuvir/velpatasvir/voxilaprevir (Vosevi)** | **12 weeks** | **All genotypes**, including **NS5A resistance** | **Salvage therapy** (treatment-experienced, resistance) |

**Treatment-Naive, No Cirrhosis:**
- **Glecaprevir/pibrentasvir × 8 weeks** (shortest, preferred if no contraindications)
- **Sofosbuvir/velpatasvir × 12 weeks** (alternative)

**Compensated Cirrhosis (Child-Pugh A):**
- **Sofosbuvir/velpatasvir × 12 weeks** OR
- **Glecaprevir/pibrentasvir × 12 weeks** (if no decompensation history)

**Decompensated Cirrhosis (Child-Pugh B/C):**
- **Sofosbuvir/velpatasvir × 12 weeks** (+ **ribavirin** if Child-Pugh C)
- **Avoid protease inhibitors** (glecaprevir/pibrentasvir contraindicated in decompensation)

### **Direct-Acting Antivirals (DAA) Classes:**

**NS5A Inhibitors:**
- **Velpatasvir**, ledipasvir, daclatasvir
- High barrier to resistance (when combined)

**NS5B Polymerase Inhibitors:**
- **Sofosbuvir** (nucleotide analog)
- Backbone of most regimens, high barrier to resistance

**NS3/4A Protease Inhibitors:**
- **Glecaprevir**, **pibrentasvir**, grazoprevir
- Contraindicated in decompensated cirrhosis

### **Monitoring:**

**Baseline:**
- **HCV RNA (quantitative)**, **HCV genotype** (not always needed with pangenotypic regimens)
- **CBC, CMP, LFTs**
- **Fibrosis assessment:** FibroScan, FIB-4, APRI, or biopsy
- **HBV serology** (HBsAg, anti-HBc, anti-HBs) - risk of HBV reactivation
- **HIV test**, **hepatitis A immunity**

**On Treatment:**
- **No routine monitoring** needed (highly effective, well-tolerated)
- **HCV RNA at week 4** optional (assess adherence/response)

**Post-Treatment:**
- **HCV RNA at 12 weeks** after completion (SVR12 = cure)
- **If SVR12:** **Cured**, lifelong immunity does NOT develop (can be reinfected)

## Key Points

### **SVR (Sustained Virologic Response) = Cure:**
- **SVR12:** HCV RNA undetectable 12 weeks after treatment
- **SVR12 = SVR24** (>99% correlation)
- **Benefits:** Prevents cirrhosis progression, reduces HCC risk (but does not eliminate if cirrhosis present), improves survival

### **Treatment Failure:**
- **Rare (<5%)** with current DAA regimens
- **Causes:** Nonadherence, resistance-associated substitutions (RAS), drug interactions
- **Management:** Resistance testing (NS5A, NS3, NS5B RAS) → retreatment with resistance-guided regimen (often sofosbuvir/velpatasvir/voxilaprevir)

### **HBV Reactivation During HCV Treatment:**
- **Screen all patients** for HBV (HBsAg, anti-HBc) before starting DAAs
- **If HBsAg+:** Monitor HBV DNA monthly OR start HBV treatment (tenofovir/entecavir) during HCV therapy
- **Can be fatal** if not recognized

### **Drug Interactions:**
- **Sofosbuvir:** Minimal interactions
- **Glecaprevir/pibrentasvir:** **Avoid with atazanavir**, rifampin
- **Velpatasvir:** **Avoid with PPIs** (requires gastric acid), use H2 blockers with caution
- **Always check interactions** (especially with antiretrovirals, anticonvulsants, statins)

### **HCV and Pregnancy:**
- **Screen all pregnant women** for HCV (universal screening now recommended)
- **Do NOT treat during pregnancy** (DAAs not studied, wait until postpartum)
- **Vertical transmission:** 5-6% (higher if HIV co-infected or high viral load)
- **Breastfeeding:** Safe (HCV not transmitted via breast milk)

### **HCC Surveillance After SVR:**
- **Continue surveillance if cirrhosis** (ultrasound ± AFP every 6 months)
- **SVR reduces HCC risk** but does NOT eliminate (especially if cirrhosis)
- **Can stop surveillance** if no cirrhosis or regression of fibrosis after SVR

### **Clinical Pearls:**
- **Treat ALL HCV RNA+ patients** (regardless of fibrosis)
- **Pangenotypic DAAs:** Sofosbuvir/velpatasvir × 12 weeks OR glecaprevir/pibrentasvir × 8 weeks
- **SVR12 = cure** (>95% cure rate)
- **Screen for HBV** before treatment (prevent reactivation)
- **Glecaprevir/pibrentasvir contraindicated** in decompensated cirrhosis
- **Continue HCC surveillance** if cirrhosis (even after SVR)
- **No lifelong immunity** (can be reinfected)

## Sources

- [AASLD/IDSA: HCV Guidelines 2024]
- [EASL: HCV Management 2024]

## Media

N/A
